ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Peter MacCallum Cancer Centre at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Peter MacCallum Cancer Centre takes part in 24 sessions at ESMO 2026 in Madrid. Its program spans treatment strategies and biomarkers across prostate, lung, melanoma and other cancers. Topics include radioligand therapy for advanced prostate cancer and blood-based DNA tests linked to treatment response and progression.
| Organization | ESMO 2026 Attendance |
|---|---|
Peter MacCallum Cancer Centre Melbourne, Australia | |
Public cancer hospital and research centre in Melbourne, Australia, affiliated with the University of Melbourne. | Talk Fri Oct 23 13:30 Abstract Fri Oct 23 14:02–14:07 2219RO - Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metastatic castration-sensitive prostate cancer (mCSPC) Genitourinary cancersGastrointestinal cancers Abstract Fri Oct 23 14:29–14:34 2222RO - Patient-reported outcomes (PROs) in men with metastatic castration-sensitive prostate cancer (mCSPC) and homologous recombination repair (HRR) gene alterations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from the phase 3 TALAPRO-3 study Genitourinary cancersGastrointestinal cancers Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Chair Fri Oct 23 16:15–17:15 Talk Fri Oct 23 16:55–17:15 Optimising radioligand therapy Genitourinary cancers Abstract Sat Oct 24 09:05–09:10 Chair Sat Oct 24 10:15–11:00 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Poster Sat Oct 24 12:00–12:45 Circulating antibody profiling identifies predictive biomarkers of outcome and irAEs in melanoma Melanoma & skin cancersBiomarkers & precision oncology Satellite Sat Oct 24 13:33–14:03 Satellite Sat Oct 24 14:03–14:28 Chair Sat Oct 24 16:30–18:00 Novel concepts for metastatic breast cancer: Looking to the future Breast cancerBiomarkers & precision oncology Chair Sun Oct 25 08:30–10:00 ctDNA in colorectal cancer: State-of-the-art and evolving clinical applications Gastrointestinal cancers Abstract Sun Oct 25 08:40–08:45 Talk Sun Oct 25 08:55–09:20 Abstract Sun Oct 25 10:42–10:47 Chair Sun Oct 25 12:00–12:50 Talk Sun Oct 25 12:00–12:15 Satellite Sun Oct 25 13:25–13:40 Tailoring treatments for specific patient subgroups Gastrointestinal cancersBiomarkers & precision oncology Satellite Sun Oct 25 13:55–14:25 From the clinic: Applying precision medicine in practice Gastrointestinal cancersBiomarkers & precision oncology Talk Sun Oct 25 14:45–15:05 Basis of the biology of radioligands for oncologists Sarcoma, CNS, head & neck and rare cancers Talk Sun Oct 25 15:15–16:00 Abstract Sun Oct 25 15:15–15:27 Chair Mon Oct 26 08:30–10:00 How to optimise care for patients receiving prostate cancer systemic therapy Genitourinary cancers Chair Mon Oct 26 10:15–11:45 Rapid oral 2: Basic science and translational research Biomarkers & precision oncology Chair Mon Oct 26 10:15–11:45 Rapid oral 2: Breast cancer, advanced stage Breast cancer Chair Mon Oct 26 10:15–11:30 Response-based adaptive strategies in primary metastatic kidney cancer Genitourinary cancers Abstract Mon Oct 26 10:35–10:50 Invited Discussant 4639RO, 4RO, 5RO and 4640RO Breast cancer Abstract Mon Oct 26 10:57–11:09 Invited Discussant 385RO, 4252RO, 386RO Biomarkers & precision oncology Talk Mon Oct 26 11:00–11:20 Timing and optimal local treatment for metastatic disease Genitourinary cancers Talk Mon Oct 26 13:05–13:15 |
Find decision makers at Peter MacCallum Cancer Centre
Tell us what you sell and we’ll find the people at Peter MacCallum Cancer Centre most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction